Postmarketing analysis of aflibercept-related sterile intraocular inflammation

• Published in: JAMA ophthalmology Vol. 133; no. 4; p. 421
• Main Authors: Hahn, Paul, Chung, Mina M, Flynn, Jr, Harry W, Huang, Suber S, Kim, Judy E, Mahmoud, Tamer H, Sadda, SriniVas R, Dugel, Pravin U
• Format: Journal Article
• Language: English
• Published: United States 01.04.2015
• Subjects: Aged; Aged, 80 and over; Angiogenesis Inhibitors - adverse effects; Choroidal Neovascularization - drug therapy; Endophthalmitis - chemically induced; Endophthalmitis - diagnosis; Endophthalmitis - drug therapy; Eye Pain - diagnosis; Eye Pain - drug therapy; Female; Glucocorticoids - therapeutic use; Humans; Intravitreal Injections; Macular Degeneration - drug therapy; Male; Middle Aged; Product Surveillance, Postmarketing - statistics & numerical data; Receptors, Vascular Endothelial Growth Factor - adverse effects; Recombinant Fusion Proteins - adverse effects; Retinal Vein Occlusion - drug therapy; Retrospective Studies; Time Factors; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity

Aflibercept-related sterile inflammation, an event that is poorly understood, has been the subject of ongoing postmarketing reports. To analyze cases of aflibercept-related sterile inflammation reported to the American Society of Retina Specialists (ASRS) Therapeutic Surveillance Committee (TSC), an...